Literature DB >> 11976740

Structural skeletal impairment induced by immunosuppressive therapy in rats: cyclosporine A vs tacrolimus.

Mohamed Abdelhadi1, Bo-Göran Ericzon, Kjell Hultenby, Göran Sjöden, Finn P Reinholt, Jörgen Nordenström.   

Abstract

The exact role of immunosuppressive drugs in the development of osteoporosis and pathologic fractures frequently reported in patients following organ transplantation is still not known. In two experiments, the effects of immunosuppressive drugs were studied on growing rats allocated randomly into five groups of eight rats each which received either FK506 (1.5 mg/kg or 3 mg/kg) or cyclosporine A (15 mg/kg or 30 mg/kg) for 28 days by daily oral gavage. In experiment I ( n=40), bone mineral content (BMC) of the femur by dual energy X-ray absorptiometry (DXA), and bone ash weight were measured. In experiment II ( n=40), stereologic measurements of decalcified tibiae were carried out. The BMC and ash weight values of the whole femur were significantly lower both in the low- and high-dose FK506 groups as well as in the high-dose CsA group. Decalcified sections showed lower volume density of trabecular bone of the tibial metaphysis in both CsA-treated groups and in the high-dose FK506 group. Furthermore, the volume density of the hypertrophic zone volume of the growth plate was higher in high-dose CsA-treated rats. Our data demonstrate that both CsA and FK506 have adverse effects on bone and that high doses of CsA or FK506 alter both cortical and trabecular bone with subsequent osteopenia. In addition, CsA-treated groups showed histological changes in some aspect resembling rickets/osteomalacia.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11976740     DOI: 10.1007/s00147-002-0413-1

Source DB:  PubMed          Journal:  Transpl Int        ISSN: 0934-0874            Impact factor:   3.782


  6 in total

1.  Pamidronate and osteoporosis prevention in liver transplant recipients.

Authors:  Pietra Pennisi; Andrea Trombetti; Emiliano Giostra; Gilles Mentha; René Rizzoli; Carmelo E Fiore
Journal:  Rheumatol Int       Date:  2006-08-31       Impact factor: 2.631

2.  A collagen-based hydrogel containing tacrolimus for bone tissue engineering.

Authors:  Mir Hamed Nabavi; Majid Salehi; Arian Ehterami; Farshid Bastami; Hassan Semyari; Maryam Tehranchi; Mir Ahmad Nabavi; Hossein Semyari
Journal:  Drug Deliv Transl Res       Date:  2020-02       Impact factor: 4.617

3.  Autologous chondrocyte implantation to repair knee cartilage injury: ultrastructural evaluation at 2 years and long-term follow-up including muscle strength measurements.

Authors:  Sverre Løken; Tom C Ludvigsen; Turid Høysveen; Inger Holm; Lars Engebretsen; Finn P Reinholt
Journal:  Knee Surg Sports Traumatol Arthrosc       Date:  2009-07-02       Impact factor: 4.342

4.  Sirolimus and tacrolimus rather than cyclosporine A cause bone loss in healthy adult male rats.

Authors:  Mercedes Rubert; Mercedes Montero; David Guede; Jose-Ramón Caeiro; Marta Martín-Fernández; Manuel Díaz-Curiel; Concepción de la Piedra
Journal:  Bone Rep       Date:  2015-05-14

5.  Use of alendronate sodium (Fosamax) to ameliorate osteoporosis in renal transplant patients: a case-control study.

Authors:  Wen-Hung Huang; Shen-Yang Lee; Cheng-Hao Weng; Ping-Chin Lai
Journal:  PLoS One       Date:  2012-11-20       Impact factor: 3.240

6.  IINFLUENCE OF THE IMMUNOSUPPRESSANT TACROLIMUS (FK-506) ON THE FLEXURAL STRENGTH OF FEMUR: A STUDY IN RATS.

Authors:  Matheus Melo Pithon; Ana Carolina Dias Viana de Andrade; Vinícius de Brito Rodrigues; Rogério Lacerda Dos Santos
Journal:  Rev Bras Ortop       Date:  2015-11-17
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.